RS50073B - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents

Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Info

Publication number
RS50073B
RS50073B YUP-869/01A YUP86901A RS50073B RS 50073 B RS50073 B RS 50073B YU P86901 A YUP86901 A YU P86901A RS 50073 B RS50073 B RS 50073B
Authority
RS
Serbia
Prior art keywords
flt1
domain
vegf
fcacl
vegf receptor
Prior art date
Application number
YUP-869/01A
Other languages
English (en)
Serbian (sr)
Inventor
Nicholas J. Papadopoulos
Samuel Davis
George D. Yancopoulos
Original Assignee
Regeneron Pharmaceuticals I.N.C.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals I.N.C., filed Critical Regeneron Pharmaceuticals I.N.C.,
Publication of YU86901A publication Critical patent/YU86901A/sh
Publication of RS50073B publication Critical patent/RS50073B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
YUP-869/01A 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama RS50073B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (2)

Publication Number Publication Date
YU86901A YU86901A (sh) 2004-05-12
RS50073B true RS50073B (sr) 2009-01-22

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-869/01A RS50073B (sr) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Country Status (32)

Country Link
EP (2) EP1183353B1 (cg-RX-API-DMAC7.html)
JP (2) JP4723140B2 (cg-RX-API-DMAC7.html)
KR (1) KR100659477B1 (cg-RX-API-DMAC7.html)
CN (3) CN103349781B (cg-RX-API-DMAC7.html)
AT (2) ATE293164T1 (cg-RX-API-DMAC7.html)
AU (2) AU779303B2 (cg-RX-API-DMAC7.html)
BE (1) BE2013C029I2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0011407B8 (cg-RX-API-DMAC7.html)
CA (1) CA2376379C (cg-RX-API-DMAC7.html)
CY (2) CY1108883T1 (cg-RX-API-DMAC7.html)
CZ (2) CZ303656B6 (cg-RX-API-DMAC7.html)
DE (2) DE60019415T2 (cg-RX-API-DMAC7.html)
DK (2) DK1544299T3 (cg-RX-API-DMAC7.html)
ES (2) ES2319305T3 (cg-RX-API-DMAC7.html)
FR (1) FR13C0028I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20010908B1 (cg-RX-API-DMAC7.html)
HU (3) HU229156B1 (cg-RX-API-DMAC7.html)
IL (3) IL146890A0 (cg-RX-API-DMAC7.html)
LT (1) LTC1183353I2 (cg-RX-API-DMAC7.html)
LU (1) LU92195I2 (cg-RX-API-DMAC7.html)
ME (2) MEP3208A (cg-RX-API-DMAC7.html)
MX (1) MXPA01012630A (cg-RX-API-DMAC7.html)
NO (4) NO330775B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ515913A (cg-RX-API-DMAC7.html)
PL (1) PL208247B1 (cg-RX-API-DMAC7.html)
PT (2) PT1544299E (cg-RX-API-DMAC7.html)
RS (1) RS50073B (cg-RX-API-DMAC7.html)
RU (1) RU2265661C2 (cg-RX-API-DMAC7.html)
SK (1) SK287332B6 (cg-RX-API-DMAC7.html)
UA (1) UA74146C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000075319A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200110068B (cg-RX-API-DMAC7.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2002248372B8 (en) 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
ES2278333T3 (es) * 2003-03-28 2007-08-01 Regeneron Pharmaceuticals, Inc. Antagonistas de vegf para el tratamiento de la diabetes.
MX351062B (es) * 2003-05-16 2017-09-29 Acorda Therapeutics Inc Proteinas de fusion para el tratamiento del snc.
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
JP2007501239A (ja) * 2003-08-06 2007-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
EP1750757B1 (en) 2004-05-18 2013-03-13 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
DK1767546T3 (da) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse
CN101102786A (zh) * 2004-06-10 2008-01-09 瑞泽恩制药公司 施用并利用vegf抑制剂治疗人类癌症的方法
US20050281822A1 (en) * 2004-06-18 2005-12-22 Cedarbaum Jesse M Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
DK2586459T3 (en) 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
PL1962895T3 (pl) † 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
ES2473610T3 (es) 2006-10-10 2014-07-07 Acorda Therapeutics, Inc. Composiciones y métodos de uso de mutantes de condroitinasa ABCI
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN101838329A (zh) 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
AR081361A1 (es) * 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
EP3539991A1 (en) * 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP3222285A1 (en) 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
PL3065761T3 (pl) 2013-11-05 2020-05-18 Allergan, Inc. Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN112826934A (zh) 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
MX382662B (es) 2015-11-18 2025-03-11 Sio2 Medical Products Inc Envase farmacéutico para formulaciones oftálmicas.
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
DK3384049T3 (da) 2015-12-03 2023-10-02 Regeneron Pharma Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
EP3717636B1 (en) 2017-11-27 2023-03-08 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
US11460452B2 (en) * 2017-12-13 2022-10-04 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
ES3009668T3 (en) * 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
JP2022546082A (ja) 2019-09-03 2022-11-02 アムジエン・インコーポレーテツド 薬物送達のための注入デバイス及び注入デバイスのためのパッケージ
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
KR20220110555A (ko) 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021226754A1 (en) 2020-02-24 2022-07-07 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023092324A1 (zh) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
EP4588469A1 (en) 2022-09-16 2025-07-23 Qilu Pharmaceutical Co., Ltd. Stable high-concentration self-buffering pharmaceutical composition
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
WO2000075319A1 (en) 2000-12-14
EP1183353B1 (en) 2005-04-13
EP1544299B1 (en) 2008-12-17
ES2237429T3 (es) 2005-08-01
HRP20010908B1 (en) 2006-05-31
IL146890A0 (en) 2002-08-14
DK1544299T3 (da) 2009-03-23
BRPI0011407B8 (pt) 2021-05-25
CN103349781A (zh) 2013-10-16
CA2376379A1 (en) 2000-12-14
CZ20014387A3 (cs) 2002-10-16
AU2005201365B2 (en) 2007-08-09
DE60041159D1 (de) 2009-01-29
HK1043388A1 (en) 2002-09-13
EP1544299A1 (en) 2005-06-22
NO20100656L (no) 2002-02-08
ME00024B (me) 2010-02-10
SK287332B6 (sk) 2010-07-07
CY2013019I2 (el) 2015-11-04
NO2013010I1 (no) 2013-06-17
NO332559B1 (no) 2012-10-29
NO20016036D0 (no) 2001-12-10
NO20016036L (no) 2002-02-08
IL146890A (en) 2008-07-08
CN103349781B (zh) 2015-04-01
CA2376379C (en) 2007-08-07
PL208247B1 (pl) 2011-04-29
AU779303B2 (en) 2005-01-13
JP2003501089A (ja) 2003-01-14
HUP0201515A3 (en) 2004-12-28
HU230159B1 (hu) 2015-09-28
PL352246A1 (en) 2003-08-11
HK1185798A1 (en) 2014-02-28
NO330775B1 (no) 2011-07-11
PT1544299E (pt) 2009-03-18
MXPA01012630A (es) 2002-07-22
LU92195I2 (fr) 2013-07-15
AU5040400A (en) 2000-12-28
HU229156B1 (en) 2013-09-30
DE60019415T2 (de) 2006-03-09
CY2013019I1 (el) 2015-11-04
CZ303656B6 (cs) 2013-01-30
AU2005201365A1 (en) 2005-04-28
KR20020019070A (ko) 2002-03-09
JP4723140B2 (ja) 2011-07-13
NO2013010I2 (no) 2013-05-15
ATE417928T1 (de) 2009-01-15
CN1369009A (zh) 2002-09-11
CZ302689B6 (cs) 2011-09-07
LTPA2013009I1 (lt) 2013-06-25
YU86901A (sh) 2004-05-12
BR0011407A (pt) 2002-04-02
PT1183353E (pt) 2005-06-30
ATE293164T1 (de) 2005-04-15
FR13C0028I2 (fr) 2014-05-16
JP5273746B2 (ja) 2013-08-28
CY1108883T1 (el) 2014-07-02
CN101433715B (zh) 2013-04-17
EP1183353A1 (en) 2002-03-06
DK1183353T3 (da) 2005-08-08
SK17522001A3 (sk) 2003-04-01
HK1132653A1 (en) 2010-03-05
ZA200110068B (en) 2002-12-06
HUP0201515A2 (en) 2002-08-28
KR100659477B1 (ko) 2006-12-20
HRP20010908A2 (en) 2005-04-30
LTC1183353I2 (lt) 2023-02-27
JP2011024595A (ja) 2011-02-10
NO2022060I1 (no) 2022-12-21
HUS1300052I1 (hu) 2016-08-29
IL190234A0 (en) 2008-11-03
MEP3208A (xx) 2010-02-10
BRPI0011407B1 (pt) 2018-09-25
BE2013C029I2 (cg-RX-API-DMAC7.html) 2019-03-06
FR13C0028I1 (fr) 2013-06-14
DE60019415D1 (de) 2005-05-19
NZ515913A (en) 2004-01-30
UA74146C2 (uk) 2005-11-15
CN100523187C (zh) 2009-08-05
CN101433715A (zh) 2009-05-20
RU2265661C2 (ru) 2005-12-10
ES2319305T3 (es) 2009-05-06

Similar Documents

Publication Publication Date Title
RS50073B (sr) Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7704500B2 (en) Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides
CA2588221C (en) Modified chimeric polypeptides with improved pharmacokinetic properties
HK1043388B (en) Modified chimeric polypeptides with improved pharmacokinetic properties